Journal of Oncology Medicine & Practice

ISSN: 2576-3857

Open Access

Volume 7, Issue 1 (2022)

Review Article Pages: 1 - 7

Clinical Characteristics and Prognosis of Pediatric Patients with Acute Lymphoblastic Leukemia Relapse in Saudi Pediatric Age Group – Single Center Experience

Esra Muhimid*, Hala Omer, Esraa Al-Qasim, Omyma Ali, Saif El-Deen Al-Horani and Saad AL-Damaa

Context: Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer worldwide, and it accounts for 30% of all cancer cases in children of Saudi Arabia. Relapsed leukemia is the fourth malignant disease in pediatrics.

Aim: This study aims to describe the clinical characteristics and outcomes of pediatric Relapsed ALL.

Settings and design: This retrospective study was conducted at a single tertiary hospital in Saudi Arabia.

Methods and data analysis: Clinical data and outcomes of all cases with relapsed acute lymphoblastic leukemia under age of 16 year diagnosed and treated from 1 January 2012 till 31 December 2020. All patients' data and information were retrieved from patients’ hard and electronic medical records and collected in REDCap system. Data analysis was done by using Statistical Package for the Social Sciences (SPSS) program version.

Results: Within the first four years of the study period, 155 cases were diagnosed with acute leukemia. In this study the relapse rate for acute lymphoblastic leukemia was 13% with overall survival about 47%, and the disease progression related mortality was 54%, while the treatment related mortality was 45% with overall mortality of 52%.

Conclusion: Relapsed ALL becomes a serious problem in pediatric oncology with relatively poor outcomes. The difficulty in treating relapse disease with satisfying results compels us to enhance the therapy for the newly diagnosed patients at the front lines considering more effective and better treatment options. Promising new molecular and immunological targeted therapies and improved HSCT technologies should be rapidly integrated into trials for subsets of higher-risk patients at initial diagnosis. Further refining of the risk stratification with the increased focus on the importance of analyzing detailed cytogenetics and molecular data in the era of application of next-generation sequencing followed subsequently by tailored risk-adapted therapy is the cornerstone of modern relapse therapy. International collaboration is essential to serve as a platform for progress in the treatment of relapsed childhood ALL.

Research Article Pages: 1 - 4

Treatment of Liver Cancer Using Specifically Targeted PLGAbased Paclitaxel Nanoparticle

Ying Liu*

We have designed a nanoparticle drug delivery system. The system included PLGA, paclitaxel (PTX) and transferrin (TF). This system can specifically target to liver cancer cells through intravenously administration. The PLGA-PTX-TF nanoparticles show excellent liver cancer treatment effect (IC50 4.79 g/mL) and are dose dependent in vitro. The PLGA-PTX-TF nanoparticle also show noticeable anti-tumor efficacy in vivo compared to PLGA-PTX (anti-cancer rate: 79.09% vs. 35.47%). Therefore, PLGA-PTX-TF nanoparticles can be considered as an effective anticancer drug delivery system for liver cancer therapy for the clinical use.

Editorial Pages: 1 - 1

An Overview of Cancer Biology

Nafisa Begum*

Share this article
Commentary Pages: 1 - 1

Multiple Myeloma: An Overview

Sonalisha Sahoo*

Share this article

50+ Million Readerbase

Journal Highlights

Google Scholar citation report
Citations: 715

Journal of Oncology Medicine & Practice received 715 citations as per Google Scholar report

Journal of Oncology Medicine & Practice peer review process verified at publons

Indexed In

arrow_upward arrow_upward